Table 1.

Characteristics of patients in the Australian Pancreatic Cancer Genome Initiative cohort who underwent resection of pancreatic ductal adenocarcinoma according to tumour location

	Head			Body and tail
	No. of patients* (n = 426)	Median DSS (months)	P ‡	No. of patients* (n = 92)	Median DSS (months)	P ‡
Age (years)†	68·0 (28·0–88·0)			70·5 (28·0–86·0)
Mean	66·5			67·8
Sex ratio (M : F)	213 : 213		0·904	45 : 47		0·168
Outcome
Follow-up (months)†	48 (18–164)			45 (32–136)
Died
Pancreatic cancer	196 (46·0)			47 (51)
Other	10 (2·3)			5 (5)
Unknown	0 (0)			0 (0)
Alive	215 (50·5)			40 (43)
Lost to follow-up	5 (1·2)			0 (0)
Tumour stage			< 0·001			0·018
I	24 (5·6)	56·6		8 (9)	51·9
II	400 (93·9)	21·0		74 (80)	13·0
III	1 (0·2)	20·0		1 (1)	21·0
IV	1 (0·2)	5·7		9 (10)	7·6
T category			0·117			0·142
T1	16 (3·8)	31·0		5 (5)	73·0
T2	34 (8·0)	32·0		14 (15)	15·8
T3	375 (88·0)	21·0		72 (78)	11·6
T4	1 (0·2)	20·0		1 (1)	21·0
N category			0·004			0·724
N0	134 (31·5)	25·2		35 (39)	12·0
N1	292 (68·5)	20·7		55 (61)	13·0
Tumour grade			0·012			0·903
I	32 (7·5)	38·1		9 (10)	15·8
II	283 (66·6)	23·0		57 (63)	12·1
III	107 (25·2)	17·0		23 (25)	13·0
IV	3 (0·7)	13·0		2 (2)	9·0
Tumour size (mm)			0·005			0·004
≤ 20	92 (21·6)	32·0		9 (10)	72·6
> 20	333 (78·4)	19·0		80 (87)	12·0
Surgical margins (R0 = 0 mm)			< 0·001			0·152
Clear	285 (66·9)	25·2		53 (58)	14·0
Involved	141 (33·1)	16·7		39 (42)	11·4
Perineural invasion			0·020			0·556
No	94 (22·5)	29·7		20 (22)	13·0
Yes	324 (77·5)	20·0		69 (78)	12·1
Vascular invasion			0·002			0·045
No	193 (46·8)	25·0		41 (47)	15·4
Yes	219 (53·2)	19·4		46 (53)	11·6
Adjuvant chemotherapy			< 0·001			0·013
< 3 cycles	249 (58·7)	16·5		61 (66)	9·3
≥ 3 cycles	175 (41·3)	29·9		31 (34)	17·0

^*With percentages in parentheses unless indicated otherwise;

^†values are median (range). Data were missing for some variables. DSS, disease-specific survival.

^‡Log rank test.